Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 17:3:103430.
doi: 10.1016/j.gimo.2025.103430. eCollection 2025.

Updated ACMG/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels

Emma H Wilcox  1   2 , Ryan F Webb  1 , Kezang C Tshering  1 , Madeline Y Hughes  1 , Hélène Cavé  3 , Marina T DiStefano  1 , Hannah Dziadzio  1 , Kate Garber  4 , Bruce D Gelb  5 , Karen W Gripp  6 , Shoji Ichikawa  7 , Jennifer A Lee  8 , Hannah McCurry  1 , Marco Tartaglia  9 , Bradley Williams  10 , Martin Zenker  11 , Lisa M Vincent  12 , Heather Mason-Suares  13 ; ClinGen RASopathy Expert Panel
Collaborators, Affiliations

Updated ACMG/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels

Emma H Wilcox et al. Genet Med Open. .

Abstract

Purpose: The ClinGen RASopathy (RAS) Variant Curation Expert Panel (VCEP) previously established RASopathy specifications to the American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology (AMP) variant classification framework for more consistent and accurate variant classification. Advances in the understanding of RASopathies and new clinical genetic testing algorithms required updated specifications.

Methods: The RAS Gene Curation Expert Panel recurated 6 gene-disease relationships, and the RAS VCEP evaluated the previous specifications to develop updated RASopathy specifications for the ACMG/AMP framework. The performance of these updated specifications was tested by reassessing 59 previously classified variants and 88 new pilot variants.

Results: Five gene-disease relationships were upgraded to Definitive, whereas 1 was upgraded to Moderate. Updated specifications were applied to 11 ACMG/AMP criteria for disorders with a dominant inheritance, 3 criteria for recessive inheritance, and 4 criteria to align with recommendations from the ClinGen Sequence Variant Interpretation Working Group. Assessment of variants demonstrated no major shifts in classifications compared with previous RAS VCEP or ClinVar classifications.

Conclusion: Updated RASopathy specifications improve the classification of variants associated with recessive disease and observed in exome/genome cases. Most of these specifications may also be used as a baseline for other rare Mendelian disorders.

Keywords: ClinGen; Noonan; RASopathy; Ras/MAPK; Variant interpretation.

PubMed Disclaimer

Conflict of interest statement

Bradley Williams and Lisa M. Vincent work for a for-profit genetic testing center. Bruce D. Gelb receives royalties from GeneDx, Correlegan, LabCorp, and Prevention Genetics; consulted for Day One BioPharmaceuticals, BioMarin; and had sponsored research agreements from Day One BioPharmaceuticals, Onconova. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Rare exome variant ensemble learner (REVEL) scores of variation in 9 RASopathy genes. A. Box plot of the REVEL scores for 40 pathogenic and 32 benign variants. See Materials and Methods for number of variants in each gene. B. Box plot of the REVEL scores for 83 pathogenic, 24 likely pathogenic variants, 24 likely benign variants, and 37 benign variants.
Figure 2
Figure 2
Decision tree for applying autosomal recessive or autosomal dominant guidelines to LZTR variants. ACMG, American College of Medical Genetics and Genomics; AD, autosomal dominant; AF, allele frequency; AR, autosomal recessive; LoF, loss-of-function; VUS, variant of uncertain significance.
See this image and copyright information in PMC

References

    1. Tidyman W.E., Rauen K.A. Pathogenetics of the RASopathies. Hum Mol Genet. 2016;25(R2):R123–R132. doi: 10.1093/hmg/ddw191. - DOI - PMC - PubMed
    1. Digilio M.C., Lepri F., Baban A., et al. RASopathies: clinical diagnosis in the first year of life. Mol Syndromol. 2011;1(6):282–289. doi: 10.1159/000331266. - DOI - PMC - PubMed
    1. Amendola L.M., Jarvik G.P., Leo M.C., et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am J Hum Genet. 2016;98(6):1067–1076. doi: 10.1016/j.ajhg.2016.03.024. - DOI - PMC - PubMed
    1. Seifert B.A., McGlaughon J.L., Jackson S.A., et al. Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. Genet Med. 2019;21(7):1507–1516. doi: 10.1038/s41436-018-0373-1. - DOI - PMC - PubMed
    1. Rehm H.L., Berg J.S., Brooks L.D., et al. ClinGen—the clinical genome resource. N Engl J Med. 2015;372(23):2235–2242. doi: 10.1056/NEJMsr1406261. - DOI - PMC - PubMed

LinkOut - more resources